Nifedipine

also known as Adalat · BAYA1040 · Adalat LA · Adalat OROS · Adalat XL · Xin Ran · Adalat (nifedipine) · ADALAT CC · +16 more

Other / unclassified

Developed for: essential hypertension · hypertensive disorder · hypertension, pregnancy-induced · preeclampsia · coronary artery disorder · diabetic kidney disease · Raynaud disease · ulcer of anus and rectum
+25 more
· chronic renal failure syndrome · congenital adrenal hyperplasia · diastolic heart failure · disorder of iron metabolism and transport · epilepsy · low implantation of placenta · myocardial ischemia · myocarditis · obstetric disorder · placenta praevia · primary aldosteronism · proteinuria · secondary hypertension · severe pre-eclampsia · urolithiasis · vulvitis · vulvodynia · atrial fibrillation · cerebral palsy · chronic kidney disease · levator syndrome · preterm premature rupture of the membranes · puerperal disorder · pulmonary hypertension · rectal disorder
Investigated by: Bayer · Medical College of Wisconsin · RDD Pharma Ltd · University of Arkansas · National Heart, Lung, and Blood Institute (NHLBI) · Actavis Inc.
+113 more
· Duke University · Icahn School of Medicine at Mount Sinai · Istituto Auxologico Italiano · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institute on Drug Abuse (NIDA) · Shanghai Shyndec Pharmaceutical Co., Ltd. · University of Alabama at Birmingham · University of Texas Southwestern Medical Center · Vanderbilt University · Weill Medical College of Cornell University · Adebayo Joshua Adeniyi · Ain Shams University · American University of Beirut Medical Center · Arrowhead Regional Medical Center · Assiut University · Baylor College of Medicine · Beaumont Hospital · BioPharma Services Inc. · Case Western/Metro Health · Cedars-Sinai Medical Center · Chantal Csajka · Chongqing Medical University · Christiana Care Health Services · Columbia University · Demand Investigators · Denver Health and Hospital Authority · Drexel University College of Medicine · Duke Regional Hospital · Emory University · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Food and Drug Administration (FDA) · Fundación Ramón Domínguez · Geisinger Clinic · Guangzhou First People's Hospital · Gundersen Health System · Hadassah Medical Organization · Hennepin County Medical Center, Minneapolis · Hospital Clinico Universitario de Santiago · Hospital das Clínicas de Ribeirão Preto · Indiana University · Intermountain Health Care, Inc. · Jiangsu HengRui Medicine Co., Ltd. · Johns Hopkins University · Laboratorios Richmond Colombia SAS · Laboratorios Richmond S.A.C.I.F. · Latter Day Saints Hospital · Lehigh Valley Hospital · Lyndon B Johnson General Hospital · Maimonides Medical Center · McKay-Dee Hospital · Medical University of South Carolina · Meriter Foundation · Miami Valley Hospital · Mount Sinai Hospital, New York · Natalia Valadares de Moraes · National Center for Research Resources (NCRR) · National Taiwan University Hospital · National University of Ireland, Galway, Ireland · New Jersey Medical School · New York Hospital Queens · Northwestern University · Ochsner Health System · Ohio State University · Oregon Health and Science University · Peking University First Hospital · Pontificia Universidad Catolica de Chile · Queen Mary University of London · Raed Salim · Rutgers, The State University of New Jersey · Saint Peters University Hospital · Saint Thomas Hospital, Panama · Samuel Lunenfeld Research Institute, Mount Sinai Hospital · San Francisco General Hospital · Sana'a University · all 119 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (2)	US (FDA)	PROCARDIA	—	1984-11-20 – 1986-07-24	fda.gov ↗
Approved	US (FDA)	PROCARDIA	—	1981-12-31	fda.gov ↗

Trials 76 · started per year

today

US approved 1981

198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT03027674	Aug 2016	Raynaud disease, dermatomyositis, systemic lupus erythematosus, systemic sclerosis	Pontificia Universidad Catolica de Chile	Completed	No outcome recorded
Phase 111 trials
Phase 1	NCT05989581	Apr 2024 → Dec 2026 expected	hypertension, pregnancy-induced	University of Alabama at Birmingham	Recruiting	No outcome recorded
Phase 1	NCT03245307	Aug 2017 → Apr 2018	—	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT03100838	Mar → Dec 2017	—	Food and Drug Administration (FDA)	Completed	No outcome recorded
Phase 1	NCT03136666	Apr → Jun 2010	—	Bayer	Completed	No outcome recorded
Phase 1	NCT01068847	Feb 2010 → Oct 2012	drug dependence	University of Arkansas	Completed	No outcome recorded
Phase 1	NCT00733239	Aug 2008 → Oct 2010	opiate dependence	University of Arkansas	Completed	No outcome recorded
Phase 1	NCT00712738	Jun 2008 → Sep 2010	disorder of iron metabolism and transport, thalassemia	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 1	NCT00593463	Sep 2006 → May 2010	drug dependence	University of Arkansas	Completed	No outcome recorded
Phase 1	NCT00865891	Jul 2005	—	Actavis Inc.	Completed	No outcome recorded
Phase 1	NCT00864617	May 2005	—	Actavis Inc.	Completed	No outcome recorded
Phase 1	NCT00223717	Jan 2001 → Jan 2017	hypertensive disorder	Vanderbilt University	Completed	No outcome recorded

Phase 1/25 trials
Phase 1/2	NCT02023047	Mar 2014 → Nov 2015	—	RDD Pharma Ltd	Terminated	No outcome recorded
Phase 1/2	NCT00972907	Dec 2009 → Jan 2011	ulcer of anus and rectum	RDD Pharma Ltd	Completed	No outcome recorded
Phase 1/2	NCT00194974	Jul 2004 → Mar 2005	proteinuria, toxemia of pregnancy	Weill Medical College of Cornell University	Withdrawn	No outcome recorded
Phase 1/2	NCT00816205	? → Apr 2009	—	RDD Pharma Ltd	Completed	No outcome recorded
Phase 1/2	NCT00000102	—	congenital adrenal hyperplasia	National Center for Research Resources (NCRR)	Completed	No outcome recorded
Phase 27 trials
Phase 2	NCT03949478	Feb 2021 → Jan 2025	epilepsy	University of Calgary	Unknown	No outcome recorded
Phase 2	NCT04846621	Jun 2020 → Jun 2021	—	Ain Shams University	Unknown	No outcome recorded
Phase 2	NCT02072291	Mar 2014 → Mar 2018	low implantation of placenta	Hadassah Medical Organization	Unknown	No outcome recorded
Phase 2	NCT01303783	Apr 2011 → May 2012	essential hypertension	Bayer	Completed	No outcome recorded
Phase 2	NCT00768560	Jan → May 2008	essential hypertension	Bayer	Completed	No outcome recorded
Phase 2	NCT00620724	Jan 2008 → Jun 2012	placenta praevia	University Hospital, Rouen	Completed	No outcome recorded
Phase 2	NCT01429545	Apr 2007 → Sep 2010	—	Tawam Hospital	Completed	No outcome recorded
Phase 2/32 trials
Phase 2/3	NCT03325348	Feb → Dec 2017	severe pre-eclampsia	Services Institute of Medical Sciences, Pakistan	Unknown	No outcome recorded
Phase 2/3	NCT02527109	May 2016 → Jun 2018	ulcer of anus and rectum	RDD Pharma Ltd	Completed	No outcome recorded
Phase 316 trials
Phase 3	NCT07448506	Jul 2024 → Apr 2025	essential hypertension	Laboratorios Richmond S.A.C.I.F.	Completed	No outcome recorded
Phase 3	NCT05687344	Sep 2023 → Mar 2026 overdue	hypertension, pregnancy-induced	Medical College of Wisconsin	Active not recruiting	No outcome recorded
Phase 3	NCT04298034	Jul 2020 → Jun 2025 overdue	preeclampsia	Medical College of Wisconsin	Active not recruiting	No outcome recorded
Phase 3	NCT02725736	Mar 2016 → Mar 2018	—	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
Phase 3	NCT01360034	Dec 2015 → May 2016	obstetric disorder	Saint Thomas Hospital, Panama	Unknown	No outcome recorded
Phase 3	NCT02132533	May 2014 → Oct 2018	—	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 3	NCT01788358	Feb 2013 → May 2014	essential hypertension	Bayer	Completed	No outcome recorded
Phase 3	NCT01314859	Jul 2011 → Jul 2012	—	Hospital Clinico Universitario de Santiago	Withdrawn	No outcome recorded
Phase 3	NCT01294215	Feb → Nov 2011	hypertensive disorder	Bayer	Completed	No outcome recorded
Phase 3	NCT01355367	Jan → Sep 2011	essential hypertension	Bayer	Completed	No outcome recorded
Phase 3	NCT00713011	Nov 2008 → Mar 2009	diabetic kidney disease, hypertensive disorder	Bayer	Withdrawn	No outcome recorded
Phase 3	NCT00496184	Apr 2006 → Oct 2007	vulvitis, vulvodynia	Western Galilee Hospital-Nahariya	Completed	No outcome recorded
Phase 3	NCT00137501	May 2003 → Jan 2009	—	American University of Beirut Medical Center	Terminated	No outcome recorded
Phase 3	NCT00004266	Aug 1993 → Jul 1999	diabetic kidney disease	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 3	NCT00000530	Sep 1992 → Jun 1998	Raynaud disease, heart disorder	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 3	NCT00000478	Nov 1990 → Jun 1997	coronary artery disorder, myocardial ischemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded

Phase 427 trials
Phase 4	NCT07659665	Aug → Dec 2026 expected	hemorrhoid	Sana'a University	Not yet recruiting	No outcome recorded
Phase 4	NCT06915792	Jun 2025 → Jul 2027 expected	hypertension, pregnancy-induced	University of California, Los Angeles	Recruiting	No outcome recorded
Phase 4	NCT05711810	Jan 2023	Orthocoronavirinae infectious disease, myocarditis	Yang I. Pachankis	Completed	No outcome recorded
Phase 4	NCT04349124	Aug 2020 → Feb 2021	hypertension, pregnancy-induced	Duke University	Terminated	No outcome recorded
Phase 4	NCT04330300	Apr 2020 → Jul 2021	COVID-19, essential hypertension	National University of Ireland, Galway, Ireland	Suspended	No outcome recorded
Phase 4	NCT03595982	Sep 2018 → Feb 2020	hypertension, pregnancy-induced	Icahn School of Medicine at Mount Sinai	Terminated	No outcome recorded
Phase 4	NCT03298191	Oct 2017 → Apr 2018	—	Assiut University	Unknown	No outcome recorded
Phase 4	NCT03506724	Sep 2017 → Apr 2019	preeclampsia	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 4	NCT03710395	Dec 2015 → Feb 2018	—	Natalia Valadares de Moraes	Unknown	No outcome recorded
Phase 4	NCT02641821	Oct 2015 → Dec 2019	hypertensive disorder	Peking University First Hospital	Unknown	No outcome recorded
Phase 4	NCT02499822	Oct 2015 → Jul 2020	essential hypertension	Istituto Auxologico Italiano	Completed	No outcome recorded
Phase 4	NCT02299414	Jun 2015 → Apr 2022	hypertensive disorder	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 4	NCT02413515	Mar 2015 → Aug 2016	hypertensive disorder	Bayer	Completed	No outcome recorded
Phase 4	NCT02357615	Dec 2014 → Jun 2015	essential hypertension	Shanghai Shyndec Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 4	NCT02068404	Apr 2014 → Jan 2016	—	Chantal Csajka	Unknown	No outcome recorded
Phase 4	NCT02031861	Feb → Jul 2014	essential hypertension	Shanghai Shyndec Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 4	NCT01830530	May → Sep 2012	hypertensive disorder	Istituto Auxologico Italiano	Completed	No outcome recorded
Phase 4	NCT00993109	Feb 2010 → May 2011	essential hypertension	Bayer	Completed	No outcome recorded
Phase 4	NCT01021501	Dec 2009 → Dec 2010	hypertensive disorder	Guangzhou First People's Hospital	Unknown	No outcome recorded
Phase 4	NCT01010048	Oct 2009	urolithiasis	Chongqing Medical University	Unknown	No outcome recorded
Phase 4	NCT01346657	Jul 2009	—	Taipei Medical University WanFang Hospital	Completed	No outcome recorded
Phase 4	NCT00599898	Jan 2008 → Dec 2011	—	Raed Salim	Completed	No outcome recorded
Phase 4	NCT00750113	Oct 2007 → Jul 2009	hypertensive disorder	Bayer	Completed	No outcome recorded
Phase 4	NCT01518855	Mar 2004 → Apr 2005	essential hypertension	Bayer	Completed	No outcome recorded
Phase 4	NCT00672113	Dec 2003 → Aug 2004	essential hypertension	Bayer	Completed	No outcome recorded
Phase 4	NCT00244530	Jun 2001 → Oct 2005	chronic renal failure syndrome, coronary artery disorder	University of Oslo School of Pharmacy	Completed	No outcome recorded
Phase 4	NCT00173667	—	hypertensive disorder	National Taiwan University Hospital	Unknown	No outcome recorded

Phase not applicable7 trials
—	NCT06220721	Oct 2024 → Mar 2029 expected	hypertension, pregnancy-induced	Medical College of Wisconsin	Recruiting	No outcome recorded
—	NCT05686993	Apr → Sep 2023	primary aldosteronism, secondary hypertension	Queen Mary University of London	Completed	No outcome recorded
—	NCT04435210	Aug 2018 → Feb 2019	hypertensive disorder	Adebayo Joshua Adeniyi	Completed	No outcome recorded
—	NCT02168309	Jun 2014 → Jun 2015	hypertension, pregnancy-induced	Cedars-Sinai Medical Center	Completed	No outcome recorded
—	NCT01351428	Dec 2010 → Nov 2012	preeclampsia	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	Completed	No outcome recorded
—	NCT01157481	Jul 2010 → Dec 2016	diastolic heart failure	Demand Investigators	Unknown	No outcome recorded
—	NCT00525486	Dec 2007 → ?	—	The Baruch Padeh Medical Center, Poriya	Terminated	No outcome recorded

Also used as a comparator or background therapy in 69 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT06796660 Background	Sep 2025 → Dec 2027 expected	chronic kidney disease	Liu Zhanghong	Not yet recruiting	No outcome recorded
Phase 0	NCT03245970 Comparator	Apr 2017 → Feb 2020	preeclampsia	University of Tennessee Medical Center	Withdrawn	No outcome recorded
Phase 0	NCT03105661 Comparator	Apr 2017 → Dec 2019	morbid obesity, preeclampsia	University of Tennessee Graduate School of Medicine	Unknown	No outcome recorded
Phase 13 trials
Phase 1	NCT00884442 Comparator	Apr 2009	—	SocraTec R&D GmbH	Completed	No outcome recorded
Phase 1	NCT02071589 Comparator	Jan → Mar 2009	—	Reig Jofre Group	Completed	No outcome recorded
Phase 1	NCT00722215 Comparator	May 2006 → Nov 2007	chronic kidney disease, proteinuria	University of Edinburgh	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT00486824 Comparator	Apr 2007 → Dec 2012	obstetric disorder	Stanford University	Completed	No outcome recorded
Phase 26 trials
Phase 2	NCT05955040 Comparator	Jul 2023 → May 2024	hypertension, pregnancy-induced	Marshall University	Terminated	No outcome recorded
Phase 2	NCT05670028 Background	Jun 2023 → Jan 2026	ischemic stroke, vascular insufficiency disorder	Beijing Tiantan Hospital	Unknown	No outcome recorded
Phase 2	NCT01985594 Comparator	Nov 2013 → Jul 2014	—	nor zila hassan malek	Unknown	No outcome recorded
Phase 2	NCT00605072 Background	Jan 2008 → Dec 2011	cognitive impairment with or without cerebellar ataxia, hypertensive disorder	University of Southern California	Completed	No outcome recorded
Phase 2	NCT00817037 Comparator	Jul 2007 → Jul 2009	chronic kidney disease, hypertensive disorder, proteinuria	University of Edinburgh	Completed	No outcome recorded
Phase 2	NCT00810732 Comparator	May 2007 → Mar 2009	chronic kidney disease	Pfizer	Completed	No outcome recorded

Phase 2/35 trials
Phase 2/3	NCT04887818 Comparator	Jun → Dec 2021	ulcer of anus and rectum	University of Calgary	Unknown	No outcome recorded
Phase 2/3	NCT04404686 Comparator	Oct 2020 → Apr 2024	obstetric disorder	Hadassah Medical Organization	Unknown	No outcome recorded
Phase 2/3	NCT02591004 Comparator	Dec 2015 → Oct 2017	cerebral palsy	Kasr El Aini Hospital	Completed	No outcome recorded
Phase 2/3	NCT02563405 Comparator	Sep 2015 → Oct 2017	hypertensive disorder	First Affiliated Hospital of Harbin Medical University	Unknown	No outcome recorded
Phase 2/3	NCT02513927 Comparator	Aug 2015 → Oct 2017	essential hypertension	First Affiliated Hospital of Harbin Medical University	Unknown	No outcome recorded
Phase 39 trials
Phase 3	NCT05551104 Comparator	May 2023 → Dec 2027 expected	hypertension, pregnancy-induced, puerperal disorder	Loma Linda University	Recruiting	No outcome recorded
Phase 3	NCT03976063 Comparator	Oct 2019 → Nov 2026 expected	preterm premature rupture of the membranes	Assistance Publique - Hôpitaux de Paris	Active not recruiting	No outcome recorded
Phase 3	NCT03542552 Comparator	Jun 2018 → Mar 2021	placenta praevia	Assiut University	Completed	No outcome recorded
Phase 3	NCT02426177 Comparator	May 2015 → May 2016	hypertensive disorder	Dow University of Health Sciences	Unknown	No outcome recorded
Phase 3	NCT01796522 Comparator	Mar → May 2013	—	La Fe Health Research Institute	Withdrawn	No outcome recorded
Phase 3	NCT01287260 Comparator	Jan → Aug 2011	essential hypertension	Bayer	Completed	No outcome recorded
Phase 3	NCT00608140 Background	Mar 2008 → Mar 2010	heart failure, mitral valve insufficiency	Duke University	Terminated	No outcome recorded
Phase 3	NCT00713739 Comparator	Jan 2008 → Dec 2010	urolithiasis	United States Naval Medical Center, San Diego	Unknown	No outcome recorded
Phase 3	NCT00519870 Comparator	Jan → Jul 2005	pulmonary hypertension	Baskent University	Completed	No outcome recorded

Phase 422 trials
Phase 4	NCT07649668 Comparator	Nov 2025 → May 2026	—	Dr Mudassar Saeed Pansota	Completed	No outcome recorded
Phase 4	NCT07023003 Comparator	Jul 2025 → Jul 2028 expected	hypertension, pregnancy-induced	Nebraska Methodist Health System	Recruiting	No outcome recorded
Phase 4	NCT07523295 Background	May → Nov 2025	—	Medicare Hospital (Pvt) Limited	Completed	No outcome recorded
Phase 4	NCT06859554 Comparator	Mar → May 2025	anal spasm	Hafiz Muhammad Hamza	Completed	No outcome recorded
Phase 4	NCT05139238 Comparator	Jul 2022 → Aug 2025	preeclampsia	Columbia University	Terminated	No outcome recorded
Phase 4	NCT05309460 Comparator	Jun 2022 → May 2024 overdue	preeclampsia	Nebraska Methodist Health System	Recruiting	No outcome recorded
Phase 4	NCT05049616 Comparator	Oct 2021 → Jun 2022	preeclampsia	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT04790279 Comparator	Apr 2021 → Dec 2022	hypertension, pregnancy-induced	Prisma Health-Upstate	Completed	No outcome recorded
Phase 4	NCT04392375 Comparator	Jun 2020 → Apr 2022	severe pre-eclampsia	Ohio State University	Completed	No outcome recorded
Phase 4	NCT04236258 Comparator	Jan 2020 → Jun 2021	puerperal disorder, severe pre-eclampsia	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 4	NCT03449277 Comparator	Jan 2018 → Feb 2019	preeclampsia	Hossam Ahmed Abd Ellah	Unknown	No outcome recorded
Phase 4	NCT03005496 Comparator	Jan → Apr 2017	—	Indonesia University	Completed	No outcome recorded
Phase 4	NCT02940548 Comparator	Dec 2016 → Dec 2020	essential hypertension	Jing Liu	Terminated	No outcome recorded
Phase 4	NCT02438371 Comparator	May 2015 → Oct 2019	—	The University of Texas Health Science Center, Houston	Terminated	No outcome recorded
Phase 4	NCT01912677 Comparator	Apr 2015 → Sep 2017	preeclampsia	Gynuity Health Projects	Completed	No outcome recorded
Phase 4	NCT02531490 Comparator	Jan 2015 → Feb 2023	preeclampsia	Maastricht University Medical Center	Unknown	No outcome recorded
Phase 4	NCT03040752 Comparator	Jan 2015 → Jan 2017	—	Cairo University	Completed	No outcome recorded
Phase 4	NCT02583633 Comparator	Oct 2013 → Oct 2014	—	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT01167153 Comparator	May 2010 → Apr 2011	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT01071122 Comparator	Jan 2010 → Feb 2012	essential hypertension	Bayer	Completed	No outcome recorded
Phase 4	NCT01030081 Comparator	Oct 2009 → Mar 2013	hypertensive disorder	Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 4	NCT01435161 Comparator	May 2007 → Aug 2011	atrial fibrillation	The Second Affiliated Hospital of Chongqing Medical University	Completed	No outcome recorded

Phase not applicable20 trials
—	NCT07363343 Comparator	Mar 2026 → Dec 2029 expected	preeclampsia	The Cleveland Clinic	Recruiting	No outcome recorded
—	NCT06265415 Comparator	Mar 2024 → Mar 2025	severe pre-eclampsia	Sohag University	Unknown	No outcome recorded
—	NCT05343806 Comparator	Apr 2023 → Jul 2025	—	Assiut University	Completed	No outcome recorded
—	NCT05520021 Comparator	Sep → Dec 2022	—	Konya Meram State Hospital	Unknown	No outcome recorded
—	NCT05345132 Comparator	Apr 2022 → Nov 2025	—	Assiut University	Unknown	No outcome recorded
—	NCT03261375 Background	Jan 2021 → Dec 2022	essential hypertension	Shanghai Golden Leaf MedTec Co. Ltd	Completed	No outcome recorded
—	NCT04288219 Background	Mar 2020 → Jun 2021	high altitude pulmonary edema	Massachusetts General Hospital	Unknown	No outcome recorded
—	NCT04186598 Background	Jan 2020 → Sep 2023	high altitude pulmonary edema	CommonSpirit Health	Completed	No outcome recorded
—	NCT02885558 Comparator	Nov 2017 → May 2021	—	University of Southern Denmark	Completed	No outcome recorded
—	NCT03129945 Comparator	Jan 2017 → Apr 2019	obstetric disorder	University of California, Irvine	Completed	No outcome recorded
—	NCT02933593 Comparator	Aug 2016 → Jan 2017	hypertensive disorder	St. Louis University	Withdrawn	No outcome recorded
—	NCT01586286 Comparator	Jul 2012 → May 2014	levator syndrome	Vanderbilt University	Withdrawn	No outcome recorded
—	NCT00691314 Comparator	Jun 2008 → Sep 2010	atherosclerosis, transient ischemic attack	Peking Union Medical College Hospital	Completed	No outcome recorded
—	NCT00664846 Background	Apr 2008 → Dec 2010	ischemic stroke	Peking Union Medical College Hospital	Completed	No outcome recorded
—	NCT00306462 Comparator	Mar 2006 → Oct 2009	—	University of Cincinnati	Terminated	No outcome recorded
—	NCT00280462 Comparator	Aug 2005 → Apr 2006	—	Medical University of Vienna	Completed	No outcome recorded
—	NCT00811057 Comparator	Jun 2004 → Jun 2009	—	University of Mississippi Medical Center	Completed	No outcome recorded
—	NCT00684489 Comparator	Sep 2003 → Mar 2005	essential hypertension	Medical University of South Carolina	Completed	No outcome recorded
—	NCT00185952 Comparator	Nov 2001 → Jan 2007	obstetric disorder, venous thromboembolism	Stanford University	Completed	No outcome recorded
—	NCT00185900 Comparator	Apr 1999 → Jul 2005	obstetric disorder	Stanford University	Completed	No outcome recorded

Press releases naming this drug 5 releases

Date	Issuer	Release
2002-08-19	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Final Approval for Nifedipine ER 90mg Tablets tevapharm.com ↗
2001-02-07	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Final Approvals of Nifedipine XL 30mg and Etodolac ER 400mg tevapharm.com ↗
2000-12-05	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Received Final Approval for Nifedipine CC 60mg and will Launch Immediately tevapharm.com ↗
2000-09-28	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Final Approval of Nifedipine XL 60 mg and will Launched Imminently tevapharm.com ↗
2000-07-25	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Pharmaceutical Industries Ltd Announces tentative FDA Approval of Nifedipine XL, 30 mg and 60 mg tevapharm.com ↗

Evidence & citations 28 cited values

Every value below carries the sentence it was read from. 145 sources stand behind the page.

Field	Value	Cited text
Known as	nifedipine	“AIMS: To determine in hypertensive patients at high cardiovascular risk whether combining Nifedipine GITS at low dose and telmisartan reduced ambulatory and clinic blood...” PMID 21252701 ↗ Mar 2011 144 “Healthy subjects were randomly allocated to receive a single dose of either one 5 milgram (mg) nifedipine capsule or one 5 milgram (mg) nifedipine capsule plus one 600 milgram...” NCT01346657 ↗ “To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or...” NCT05670028 ↗ “Blood Pressure Control: Antihypertensive drugs such as amlodipine tablets (5 mg qd), nifedipine tablets (30 mg qd), or losartan tablets (100 mg qd) can be selected.” NCT06796660 ↗ “Nicorandil (potassium channel activator) is claimed to be as effective as Nifedipine (calcium channel blocker) for tocolysis in preterm labour” NCT04846621 ↗ “Nifedipine is a peripheral arterial vasodilator and an ideal first line antihypertensive agent due to its low maternal side-effect profile.” NCT03595982 ↗ “A comparison study between Ritodrine, magnesium sulfate and Nifedipine in terms of effect and morbidity will be conducted.” NCT03298191 ↗ “combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy” NCT00608140 ↗ “Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.” PMID 38949541 ↗ May 2024 “received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours” NCT03542552 ↗ “Amlodipine, diltiazem, felodipine, nicardipine, nifedipine, nimodipine, nitrendipine, verapamil” NCT04330300 ↗ “isradipine, nicardipine, nifedipine, nisoldipine, doxazosin” NCT00684489 ↗ “Nifedipine: 5, 10, 20 mg oral capsule may possibly be given” NCT00733239 ↗ “Nifedipine: 10, 20 mg oral capsules may possibly be given.” NCT01068847 ↗ “oral labetalol tablets and oral nifedipine tablets” NCT03449277 ↗ “or Valsartan 80mg/day or Nifedipine 30mg/day” NCT00691314 ↗ “Valsartan 80mg/day or Nifedipine 30mg/day” NCT00664846 ↗ “Nifedipine + hydrochlorothiazide” NCT03261375 ↗ NCT00306462 ↗ NCT00004266 ↗ NCT00185952 ↗ NCT00185900 ↗ NCT04186598 ↗ NCT01985594 ↗ NCT01796522 ↗ NCT02725736 ↗ NCT04288219 ↗ NCT01435161 ↗ NCT02132533 ↗ NCT02357615 ↗ NCT00864617 ↗ NCT03506724 ↗ NCT00280462 ↗ NCT07448506 ↗ NCT02168309 ↗ NCT01351428 ↗ NCT02641821 ↗ NCT03005496 ↗ NCT03040752 ↗ NCT00137501 ↗ NCT02563405 ↗ NCT02031861 ↗ NCT00605072 ↗ NCT00884442 ↗ NCT02940548 ↗ NCT00244530 ↗ NCT02426177 ↗ NCT00810732 ↗ NCT02023047 ↗ NCT03949478 ↗ NCT00000530 ↗ NCT02068404 ↗ NCT00712738 ↗ NCT03027674 ↗ NCT02513927 ↗ NCT04790279 ↗ NCT04404686 ↗ NCT04236258 ↗ NCT05345132 ↗ NCT07363343 ↗ NCT00194974 ↗ NCT01912677 ↗ NCT01518855 ↗ NCT02583633 ↗ NCT00817037 ↗ NCT05551104 ↗ NCT06220721 ↗ NCT05955040 ↗ NCT01788358 ↗ NCT02527109 ↗ NCT04435210 ↗ NCT03136666 ↗ NCT05687344 ↗ NCT00972907 ↗ NCT02071589 ↗ NCT00486824 ↗ NCT05309460 ↗ NCT03976063 ↗ NCT00593463 ↗ NCT05520021 ↗ NCT07649668 ↗ NCT05139238 ↗ NCT01071122 ↗ NCT01167153 ↗ NCT05343806 ↗ NCT03129945 ↗ NCT04349124 ↗ NCT00672113 ↗ NCT03105661 ↗ NCT01294215 ↗ NCT02885558 ↗ NCT03245970 ↗ NCT00000478 ↗ NCT06915792 ↗ NCT02072291 ↗ NCT00811057 ↗ NCT00722215 ↗ NCT05711810 ↗ NCT02499822 ↗ NCT00816205 ↗ NCT06859554 ↗ NCT00525486 ↗ NCT07659665 ↗ NCT00519870 ↗ NCT03245307 ↗ NCT00173667 ↗ NCT05989581 ↗ NCT01830530 ↗ NCT01303783 ↗ NCT01586286 ↗ NCT07023003 ↗ NCT02933593 ↗ NCT00768560 ↗ NCT00713739 ↗ NCT01355367 ↗ NCT01157481 ↗ NCT02591004 ↗ NCT06265415 ↗ NCT01360034 ↗ NCT07523295 ↗ NCT03325348 ↗ NCT01287260 ↗ NCT02413515 ↗ NCT00865891 ↗ NCT04887818 ↗ NCT00000102 ↗ NCT03100838 ↗ NCT00496184 ↗ NCT01030081 ↗ NCT00993109 ↗ NCT04298034 ↗ NCT02531490 ↗ NCT04392375 ↗ NCT03542552 ↗ NCT00599898 ↗ NCT05049616 ↗ NCT00223717 ↗ NCT01314859 ↗ NCT01429545 ↗ NCT01021501 ↗ NCT00620724 ↗ NCT02438371 ↗ NCT03710395 ↗ NCT01010048 ↗ NCT05686993 ↗
Known as	Adalat	“Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes” NCT00280462 ↗ 11 “Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 12-week treatment period.” NCT02031861 ↗ “Study drugs: amlodipine (Norvasc®) and nifedipine GITS (Adalat®)” NCT01030081 ↗ “Drug: Nifedipine GITS (Adalat, BAYA1040), 20 mg” NCT01303783 ↗ “nifedipine controlled-release tablets (Adalat)” NCT02357615 ↗ “Drug: Adalat (Nifedipine, BAYA1040)” NCT00993109 ↗ “Drug: Nifedipine (Adalat, BAYA1040)” NCT01518855 ↗ “Nifedipine (Adalat, BAYA1040)” NCT01294215 ↗ “Nifedipine (Adalat, BAYA1040)” NCT01287260 ↗ “Adalat (Nifedipine, BAYA1040)” NCT00672113 ↗ “Nifedipine (Adalat, BAYA1040)” NCT01355367 ↗ “Nifedipine (Adalat, BAYA1040)” NCT01071122 ↗
Known as	Adalat (nifedipine)	“Adalat (nifedipine)” NCT02885558 ↗
Known as	ADALAT CC	“ADALAT® CC Extended Release Tablets 60 mg” NCT00864617 ↗
Known as	Adalat CR	“Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study” NCT00768560 ↗
Known as	Adalat Crono	“Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)” NCT00884442 ↗
Known as	Adalat GITS	“Nifedipine (Adalat GITS, BAY1040)” NCT02413515 ↗
Known as	Adalat LA	“Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)” NCT00884442 ↗ 1 “Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil” NCT03136666 ↗
Known as	Adalat OROS	“Group A: nifedipine 30-60mg once daily (Nifecardia, CCPC) Group B: nifedipine 30-60 mg once daily (Adalat OROS, Bayer)” NCT00173667 ↗ 1 “Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)” NCT00884442 ↗
Known as	Adalat XL	“Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)” NCT00884442 ↗ 1 NCT00713011 ↗
Known as	Adalat XL 30	“Nifedipine GITS (Adalat® XL 30” NCT01030081 ↗
Known as	BAY1040	“Nifedipine (Adalat GITS, BAY1040)” NCT02413515 ↗
Known as	BAYA1040	“Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil” NCT03136666 ↗ 9 “Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning” NCT00768560 ↗ “Drug: Nifedipine GITS (Adalat, BAYA1040), 20 mg” NCT01303783 ↗ “Drug: Adalat (Nifedipine, BAYA1040)” NCT00993109 ↗ “Drug: Nifedipine (Adalat, BAYA1040)” NCT01518855 ↗ “Nifedipine (Adalat, BAYA1040)” NCT01287260 ↗ “Adalat (Nifedipine, BAYA1040)” NCT00672113 ↗ “Nifedipine (Adalat, BAYA1040)” NCT01071122 ↗ “Nifedipine (Adalat, BAYA1040)” NCT01355367 ↗ “Nifedipine (Adalat, BAYA1040)” NCT01294215 ↗
Known as	Coated Nifedipine Suppositories	“Drug: Coated Nifedipine Suppositories” NCT00816205 ↗
Known as	Gen-nifedipine extended release	“Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)” NCT00884442 ↗
Known as	Gen-Nifedipine XL	“Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)” NCT00884442 ↗
Known as	Nifecardia	“Group A: nifedipine 30-60mg once daily (Nifecardia, CCPC) Group B: nifedipine 30-60 mg once daily (Adalat OROS, Bayer)” NCT00173667 ↗
Known as	nifedipine (Adalat Crono, Bayer AG, Leverkusen, Germany)	“nifedipine (Adalat Crono, Bayer AG, Leverkusen, Germany)” NCT00519870 ↗
Known as	Nifedipine 60 mg, GITS	“Nifedipine 60 mg, GITS” NCT00884442 ↗
Known as	nifedipine extended release	“Subjects randomized to the treatment group will be provided the study drug (nifedipine extended release) at an initial dose of 30mg daily in 1-month supply.” NCT04349124 ↗
Known as	Nifedipine Extended-Release Tablets	“Drug: Nifedipine Extended-Release Tablets” NCT04349124 ↗
Known as	Nifedipine GITS	“Nifedipine GITS 30 mg slow release in tablets.” NCT02499822 ↗
Known as	Nifedipine: Adalat, Procardia	“Nifedipine: Adalat, Procardia” NCT01068847 ↗
Known as	Procardia XL	“extended release nifedipine (Procardia XL), a blood pressure medication” NCT00000102 ↗
Known as	Xin Ran	“Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 12-week treatment period.” NCT02031861 ↗ 1 “nifedipine controlled-release tablet (30 mg, Xin Ran)” NCT02357615 ↗
Action	Inhibit	“calcium channel antagonist” NCT00000102 ↗
Modality	Other / unclassified	“nifedipine (calcium channel blocker)” NCT01429545 ↗
Route	Other	“10 mg. sublingually every 20 minutes for three doses” NCT00185900 ↗